share_log

Goldman Sachs Initiates Coverage On Vaxcyte With Buy Rating, Announces Price Target of $135

Benzinga ·  Dec 20 20:51  · Ratings

Goldman Sachs analyst Chris Shibutani initiates coverage on Vaxcyte (NASDAQ:PCVX) with a Buy rating and announces Price Target of $135.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment